Atara Biotherapeutics
ATRA
140 hedge funds and large institutions have $1.61B invested in Atara Biotherapeutics in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 51 increasing their positions, 47 reducing their positions, and 19 closing their positions.
69% more call options, than puts
Call options by funds: $677K | Put options by funds: $401K
20% more capital invested
Capital invested by funds: $1.34B → $1.61B (+$268M)
9% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 47
0.14% more ownership
Funds ownership: 4.09% → 4.23% (+0.14%)
3% less funds holding
Funds holding: 145 → 140 (-5)
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$22.6M |
| 3 |
6CM
683 Capital Management
New York
|
+$15.8M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$7.44M |
| 5 |
JP Morgan Chase
New York
|
+$7.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$8.84M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.47M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$6.16M |
| 4 |
BM
Bridger Management
New York
|
-$5.71M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$5.3M |
ATRA Hedge Fund Activity: Q3 2021 in Review
140 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q3 2021, worth a combined $1.61B — up 20% from $1.34B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ATRA and 15 opened new positions — a net loss of 4 holders — while 47 trimmed existing stakes and 51 added.
The largest buyer was Fidelity Investments, adding an estimated $43.6M. The largest seller was Renaissance Technologies, cutting an estimated $8.84M.
- 140 institutional investors held Atara Biotherapeutics (ATRA) as of Q3 2021, down from 145 in Q2 2021.
- Funds reported $1.61B of Atara Biotherapeutics stock for Q3 2021, up 20% quarter-over-quarter.
- 15 funds opened new Atara Biotherapeutics positions in Q3 2021 and 19 closed out, a net change of -4 holders.
- The largest Atara Biotherapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $43.6M added.
- The largest Atara Biotherapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $8.84M sold.
Based on aggregated 13F filings for Q3 2021.